Verva Pharmaceuticals

Verva Pharmaceuticals Ltd. is an exciting, clinical-stage pharmaceutical company developing innovative therapies to treat metabolic diseases. Verva’s research efforts are focused on the treatment of type 2 diabetes and the prevention and reversal of obesity and related complications. We have moved rapidly since our inception in 2007 to establish a strong clinical-stage portfolio incorporating:

• A novel insulin sensitizer (VVP808) undergoing phase 2a clinical proof-of-concept testing as a treatment for type 2 diabetes.
• A dedicated program to discover and characterize the biological target by which VVP808 exerts its insulin sensitizing effect.
• A focused discovery program identifying potent next-generation diabetes therapies based on VVP808 structure and mode-of-action.
• Two Fat Blocker technologies that prevent de novo fat cell formation and have potential utility in the prevention and treatment of obesity and diabetes
• A validated discovery platform (the Gene Expression Signature Technology) that successfully identified VVP808 and can be used to identify previously-unrecognized utility of clinical and preclinical compounds as diabetes therapies.